Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An index of net bone formation relative to resorption is associated with incident fracture during the menopause transition and postmenopause.

JBMR plus·2026
Same author

Habitat-Associated Dietary Plasticity in the Japanese Weasel (<i>Mustela itatsi</i>): Fecal Analysis in a Floodplain Wetland and Comparative Synthesis.

Animals : an open access journal from MDPI·2026
Same author

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

JAMA·2026
Same author

Trait-Associated Gaps in IUCN Assessment and Conservation Prioritization for Echolocating Mammals.

Integrative zoology·2026
Same author

Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis.

JBMR plus·2026
Same author

Broadening metrics in the Lancet Countdown on health and climate change.

Lancet (London, England)·2026
Same journal

Mitochondria produce lactate to vent redox pressure.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Beyond fat storage: neuronal lipid droplets regulate whole-body metabolism.

Trends in endocrinology and metabolism: TEM·2026
Same journal

HDL resuscitates cells from ferroptosis.

Trends in endocrinology and metabolism: TEM·2026
Same journal

2-Methylbutyrylcarnitine (2MBC).

Trends in endocrinology and metabolism: TEM·2026
Same journal

Decoding growth hormone actions on human growth plate stem cells.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Androgen loss backfires: Brain gate for tumor immunity.

Trends in endocrinology and metabolism: TEM·2026
See all related articles

Related Experiment Videos

Heart drugs that affect bone.

Jennifer S Walsh1, Chris Newman, Richard Eastell

  • 1National Institute for Health Research Biomedical Research Unit for Musculoskeletal Disease at University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK.

Trends in Endocrinology and Metabolism: TEM
|December 6, 2011
PubMed
Summary
This summary is machine-generated.

Cardiovascular drugs can affect bone health, with some like nitrates showing benefits for osteoporosis and atherosclerosis. Other medications may harm bone, highlighting potential for new dual-action treatments.

Related Experiment Videos

Area of Science:

  • Bone biology and cardiovascular medicine
  • Pharmacology and therapeutic interventions
  • Interdisciplinary research in chronic diseases

Background:

  • Osteoporosis and atherosclerosis share underlying developmental mechanisms.
  • Cardiovascular medications can influence bone health, presenting both risks and benefits.
  • Understanding these drug-bone interactions is crucial for patient care.

Purpose of the Study:

  • To review the impact of cardiovascular drugs on bone health.
  • To identify drugs with potential benefits or harms to bone.
  • To explore opportunities for novel therapeutic strategies targeting bone diseases.

Main Methods:

  • Literature review of studies on cardiovascular drugs and bone health.
  • Analysis of evidence for beneficial and harmful effects of specific drug classes.
  • Synthesis of findings to identify common mechanisms and therapeutic potential.

Main Results:

  • Nitrates show evidence of benefit to bone health.
  • Statins, thiazide diuretics, and beta-blockers have weaker evidence of bone benefit.
  • Loop-acting diuretics likely harm bone, while warfarin's harm is less certain.

Conclusions:

  • Cardiovascular drug effects on bone are significant and varied.
  • Shared mechanisms between osteoporosis and atherosclerosis offer therapeutic targets.
  • Development of treatments benefiting multiple chronic conditions is a promising avenue.